CSPC Pharmaceutical Group’s Stock Price Stands at 6.14 HKD, Experiences Slight Dip of 0.16%

CSPC Pharmaceutical Group (1093)

6.14 HKD -0.01 (-0.16%) Volume: 225.54M

CSPC Pharmaceutical Group’s stock price stands at 6.14 HKD, experiencing a slight drop of -0.16% this trading session, with a significant trading volume of 225.54M. Despite the recent dip, the stock boasts a remarkable YTD increase of +28.45%, showcasing solid performance and growth potential.

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group (HKG:1093) made headlines today as it announced a reduction in its dividend to CN¥0.10. This news comes on the heels of the company’s Q1 2025 financial report, which showcased improved cash flow thanks to its innovative products. In addition, CSPC Pharmaceutical shared that its JMT203, an Anti-Gfral Monoclonal Antibody, has obtained clinical trial approval in the U.S. The company also received approval from the U.S. FDA for clinical trials of JMT203, further bolstering its position in the market. Furthermore, CSPC Pharmaceutical recently gained approval for diabetes drug trials, indicating a promising future for the company and potentially impacting its stock price movements.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With high scores in Dividend and Value, the company demonstrates strong financial performance and potential for growth. Additionally, its Resilience score indicates a stable and reliable business model, while the Growth and Momentum scores suggest opportunities for future development and market presence.

CSPC Pharmaceutical Group Limited, known for manufacturing and selling a variety of pharmaceutical products including vitamin C, antibiotics, and generic drugs, is also involved in the innovation and development of new drugs and antibiotics. With its solid performance across key factors, the company seems well-positioned for continued success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma